Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
11 July 2024 | Story André Damons | Photo supplied
From top (left to right): Dr Angélique Lewies (researcher from the Robert WM Frater Cardiovascular Research Centre within the UFS Department of Cardiothoracic Surgery), Zurika Murray (behavioural geneticist from the UFS Department of Genetics), Dr Marieka Gryzenhout (C-rated scientist and Senior Lecturer in the Department of Genetics), and Dr Jaco Wentzel (serves as the pharmaceutical industry partner and consultant for the project at FARMOVS).

In an effort to advance drug discovery and disease research, researchers from the University of the Free State (UFS), the Central University of Technology (CUT), and FARMOVS, a clinical research company associated with the UFS, is developing innovative 3D cell culture models using 3D printed mini bioreactors.

This interdisciplinary project, led by Dr Angélique Lewies, researcher from the Robert WM Frater Cardiovascular Research Centre (Frater Centre) within the UFS Department of Cardiothoracic Surgery, is creating more accurate and human-like models for this purpose, reducing the need for animal testing, and improving the safety and effectiveness of new treatments.

The project was initiated to address the challenges associated with current 3D cell culture techniques, which are often expensive and complex. Recognising the need for a more cost-effective and user-friendly solution, the researchers embarked on this collaboration to develop a novel 3D cell culture system. By making these advanced techniques more accessible, the team aims to enhance the reliability of drug testing and significantly reduce the reliance on animal experiments. This innovative approach not only promises to cut costs but also promotes ethical research practices in the scientific community.

Dr Lewies, whose research specialises in cardio-oncology (relationship between cancer treatment and heart health), particularly in understanding and preventing damage to cardiac cells caused by chemotherapy, leads the cell biology aspects of the project, focusing on the cultivation of 3D cancer spheroid and organoid cultures.

According to her, the project focuses on creating 3D cell cultures, known as spheroids and organoids, that mimic human tissues more closely. These 3D models can improve the reliability of drug testing and reduce the need for animal experiments, aligning with the 3R principles: Reduction, Replacement, and Refinement.

Creating a versatile platform

“Traditional drug discovery and disease studies often rely on flat (2D) cell cultures and animal models. While animal models are essential for understanding disease and testing drug safety, they don't always predict how humans will respond, and their use raises ethical concerns.

“We aim to develop affordable and efficient 3D-printed mini bioreactors for growing these advanced cell cultures. These bioreactors will be designed to fit into existing cell culture labs, making them accessible to researchers. By leveraging the cutting-edge 3D printing technology at CUT's Centre for Rapid Prototyping and Manufacturing (CRPM), the team hopes to create a versatile platform for various research applications,” says Dr Lewies.

She is joined in this project by UFS colleagues; Zurika Murray, a behavioural geneticist, and her colleague from the Department of Genetics, Dr Marieka Gryzenhout, a C-rated scientist and Senior Lecturer. Dr Jaco Wentzel from FARMOVS. is also involved in the project. Dr Wentzel serves as the pharmaceutical industry partner and consultant for the project. With experience in cellular biology and pharmaceuticals, he ensures that the new 3D cell culture models meet industry standards and can be effectively used in drug development. Dr Wentzel’s role is crucial in bridging the gap between academic research and practical application in the pharmaceutical industry.

Goals

According to Dr Lewies, this project aims to create more accurate and ethical models for drug testing and improving the development of new treatments. By combining expertise from engineering, biology, and mycology, the team is set to revolutionise how diseases are studied, and medicines developed. Funded by the CUT and UFS Joint Research Programme, this initiative promises to foster innovation and lead to new research collaborations.

“Cardiac cell damage, known as cardiotoxicity, can lead to serious cardiovascular diseases and is a major reason why some drugs are removed from the market. By developing 3D cancer spheroids and cardiac organoids (mini heart models), my team aims to find ways to prevent this cardiotoxicity while enhancing the effectiveness of chemotherapy drugs.

“Additionally, they are exploring the cardiotoxic effects of natural products, such as medicinal plants and mushrooms, which show potential for both anticancer and cardio-protective properties,” says Dr Lewies.

Experts

Murray is interested in how the psychedelic compounds psilocybin and psilocin affect the brain with her research focusing on the epigenome of genes within the serotonin pathway, which could explain the therapeutic potential of these compounds. “As part of this project, Murray will work with the Frater Centre to develop neuronal organoids (mini brain models) using the 3D mini-bioreactor platform.

“This will allow her to investigate the effects of psilocybin and psilocin on brain function, which have shown promise in treating mental health disorders like depression and anxiety, aiming to understand how these substances might help treat mental health issues,” says Dr Lewies.

Dr Gryzenhout brings her expertise in mycology and is responsible for cultivating medicinal mushrooms used in the project. Dr Gryzenhout's research focuses on the genetic characterisation of medicinal mushrooms and evaluating their therapeutic potential. These mushrooms produce a variety of bioactive compounds with therapeutic benefits, including anticancer activities, heart protection, and immune system support.

Her team is also approved by the South African Health Products Regulatory Authority (SAHPRA) to research the controlled psychedelic compounds psilocybin and psilocin.

Drug Discovery Goals

The project’s long-term focus is on potentially discovering new drugs to prevent and treat heart and brain diseases. Specifically, the team is working on developing therapies for cardio-oncology and neurological applications. In the realm of cardio-oncology, the goal is to find treatments that prevent cardiac cell damage and downstream cardiovascular diseases caused by cancer therapies, while still effectively targeting cancer cells. For neurological applications, the researchers are exploring the potential of drugs derived from medicinal mushrooms, including those with psychedelic properties, to treat conditions like depression, anxiety, and other mental health disorders.

News Archive

Victory lies beyond the moment
2017-12-25


 Description: 2017 Victory lies beyond the moment Tags: 2017 Victory lies beyond the moment 

Mokoena learns a new skill at the Learning Festival arranged
by the Centre for Community Engagement.
Photo: Igno van Niekerk

For Mokoena it was just a regular day. Another day. Another rush. As a taxi driver you get used to the adrenaline, taking gaps, foot on the accelerator. Alert. Honking hooters. Angry drivers.

Then it came out of nowhere. A stroke. The one side of his body was going numb. What was happening? What about his job? His income? His life?

Fast-forward a few years.

I meet Mokoena at the Learning Festival arranged by the Centre for Community Engagement, in association with Bloemshelter on the University of the Free State’s Bloemfontein Campus. A reserved young man, Mokoena is busy at one of the stands where a range of people from rural communities come to learn new skills. At no cost. They then go back to teach the skills they learnt in their communities. Job creation, that’s the philosophy: as you develop, you need to develop others. 

When I talk to Karen Venter, Head of Service Learning at the Centre for Community Engagement, the stories are overwhelming. “There was the lady who attended 19 workshops in two days. She went back to her community, shared her knowledge and became an entrepreneur helping others take care of themselves.”

New skills
Mokoena is also here to acquire new skills. After his stroke he was told by occupational therapy students about a project that teaches you to build your own house with raw materials. He takes out his cellphone with a sense of pride. Scrolls through some pictures: “This is my house. I built it from all kinds of things, cow manure, bottles, clay, other people’s rubbish.” The pictures show a house in a neat environment. Solid. Proud. A lot of healing came with building the house. Karen explains: “The physical work he was doing, pushing a wheelbarrow and working, but more than that – the knowledge that he could take charge, make a difference, work on a dream – the healing power of a sense of purpose. He became stronger and more confident.”

Victory 
Mokoena walks back to the sewing workshop he was attending before sharing his story. The buzz continues inside the Equitas Building where artisans, entrepreneurs and UFS staff are sharing their skills. Sewing machines hum away and infrequent beeps sound from a table where an excited group of non-scientists have just completed the building of circuits. Faces light up with every beep. Hands raised. Fists clenched. Victory!

But the victory lies beyond the moment. It’s in the confidence, the learning, and the sharing that will be taking place when these people go back to their communities. Some will participate in research projects; others will benefit from curricular requirements leading students into distant communities, and others will be hosting workshops at the next Learning Festival. 

And there will be more great stories. Like Mokoena’s.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept